Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jan 6:21:14-18.
doi: 10.1016/j.jdcr.2021.12.011. eCollection 2022 Mar.

Review of dupilumab-associated inflammatory arthritis: An approach to clinical analysis and management

Ryan Jay  1 , Jaimie Rodger  1   2 , Matthew Zirwas  1   2
Affiliations
Case Reports

Review of dupilumab-associated inflammatory arthritis: An approach to clinical analysis and management

Ryan Jay et al. JAAD Case Rep. .
No abstract available

Keywords: IL, interleukin; IL-13; IL-17; IL-23; IL-4; IL-4Rα; adverse effect; arthritis; arthropathy; atopic dermatitis; dupilumab; dupilumab-associated; dupilumab-induced; enthesitis; inflammatory arthritis.

PubMed Disclaimer

Conflict of interest statement

Dr Zirwas has served as an investigator, consultant, or speaker for Regeneron/Sanofi, FitBit, Genench/Novartis, L’Oreal, Aseptic MD, Leo, Janssen, Incyte, Vyne, UCB, Pfizer, Lilly, Asana, Avillion, Ortho Derm, AbbVie, Edessa Biotech, Galderma, Dermavant, Arcutis, Sol-Gel, Bausch Health, EPI Health, Concert, and Anaptys Bio. Author Jay and Dr Rodger have no conflicts of interest to declare.

References

    1. Gooderham M.J., Hong H.C., Eshtiaghi P., Papp K.A. Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018;78(3 suppl 1):S28–S36. doi: 10.1016/j.jaad.2017.12.022. - DOI - PubMed
    1. Willsmore Z.N., Woolf R.T., Hughes C., et al. Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series. Br J Dermatol. 2019;181(5):1068–1070. doi: 10.1111/bjd.18031. - DOI - PubMed
    1. Nathan J., Hughes C., Patel S., et al. AB0573 dupilumab-induced enthesitis/arthritis in patients with atopic dermatitis: a retrospective observational study. Ann Rheum Dis. 2021;80(suppl 1):1323–1324. doi: 10.1136/annrheumdis-2021-eular.1363. - DOI
    1. Sears A.V., Woolf R.T., Gribaleva E., et al. Real-world effectiveness and tolerability of dupilumab in adult atopic dermatitis: A single-centre, prospective 1-year observational cohort study of the first 100 patients treated. Br J Dermatol. 2021;184(4):755–757. doi: 10.1111/bjd.19631. - DOI - PubMed
    1. de Wijs L.E.M., van der Waa J.D., de Jong P.H.P., Hijnen D.J. Acute arthritis and arthralgia as an adverse drug reaction to dupilumab. Clin Exp Dermatol. 2020;45(2):262–263. doi: 10.1111/ced.14050. - DOI - PubMed

Publication types

LinkOut - more resources